Crucell Reports First Orders For Contract Manufacturing Agreement
with Wyeth Biotech
PRESS RELEASE
Crucell Reports First Orders For Contract Manufacturing Agreement
with Wyeth Biotech
Leiden, The Netherlands, December 15, 2006 - Dutch biotechnology
company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX)
today announced it has received its first orders for the CMO
agreement with New Jersey-headquartered Wyeth Biotech. The CMO
agreement for formulation and filing of a vaccine was finalized end
2005 and will have the first business impact for Crucell in 2007. The
vaccine will be supplied from Crucell's Swiss subsidiary.
About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a
biotechnology company focused on research, development and worldwide
marketing of vaccines and antibodies that prevent and treat
infectious diseases. Its vaccines are sold in public and private
markets worldwide. Crucell's core portfolio includes a vaccine
against hepatitis B, a fully-liquid vaccine against five important
childhood diseases, and a virosome-adjuvanted vaccine against
influenza. Crucell also markets travel vaccines, such as the only
oral anti-typhoid vaccine, an oral cholera vaccine and the only
aluminum-free hepatitis A vaccine on the market. The Company has a
broad development pipeline, with several Crucell products based on
its unique PER.C6® production technology. The Company licenses this
and other technologies to the biopharmaceutical industry. Important
partners and licensees include DSM Biologics, sanofi aventis, GSK and
Merck & Co. Crucell is headquartered in Leiden (the Netherlands),
with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the
US. The Company employs over a 1000 people. For more information,
please visit www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements that involve
inherent risks and uncertainties. We have identified certain
important factors that may cause actual results to differ materially
from those contained in such forward-looking statements. For
information relating to these factors please refer to our Form 20-F,
as filed with the U.S. Securities and Exchange Commission on July 6,
2006, and the section entitled "Risk Factors". The Company prepares
its financial statements under generally accepted accounting
principles in the United States (US GAAP) and Europe (IFRS).
For further information please contact:
Crucell N.V. For Crucell in the US:
Leonard Kruimer Redington, Inc.
Chief Financial Officer Thomas Redington
Tel. +31-(0)71-524 8722 Tel. +1 212-926-1733
Leonard.Kruimer@crucell.com tredington@redingtoninc.com
